Peptide Comparison
EnalaprilvsThymosin Beta-4
The blood pressure champion that helped millions breathe easier and live longer
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
At a Glance
Quick
comparison
Dose Range
Enalapril
2.5 mg–40 mg mg
Thymosin Beta-4
2–5 mg
Frequency
Enalapril
Once daily
Thymosin Beta-4
Twice weekly
Administration
Enalapril
Oral tablet
Thymosin Beta-4
Subcutaneous injection
Cycle Length
Enalapril
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset Speed
Enalapril
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence Level
Enalapril
Strong human trials (Phase 3 or FDA approved)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Cardiovascular Health
Long-term Protection
Quality of Life
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical Data
Compound
specifications
Enalapril
Molecular Formula
C20H28N2O5
Molecular Weight
376.4 g/mol
Half-Life
Enalapril: 1 hour; Enalaprilat (active form): 11 hours effective half-life
Bioavailability
Approximately 60% oral bioavailability when taken by mouth
CAS Number
75847-73-3
Thymosin Beta-4
Molecular Formula
C212H350N56O78S
Molecular Weight
4963
Half-Life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS Number
77591-33-4
Applications
Best
suited for
Enalapril
Managing hypertension to prevent serious complications
Enalapril is particularly well-suited for individuals focused on managing hypertension to prevent serious complications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating heart failure and improving survival rates
Enalapril is particularly well-suited for individuals focused on treating heart failure and improving survival rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting organs from damage caused by high blood pressure
Enalapril is particularly well-suited for individuals focused on protecting organs from damage caused by high blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety Profile
Side
effects
Enalapril
Common
- Dry cough
- Dizziness
- Fatigue
- Hyperkalemia
- Angioedema
Serious
- Severe allergic reaction
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research Status
Safety
& evidence
Enalapril
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Enalapril is an FDA-approved ACE inhibitor with safety data spanning over 40 years of clinical use and post-market surveillance in millions of hypertensive patients. Persistent dry cough occurs in 10-20% of patients, caused by kinase II inhibition and bradykinin accumulation. Hyperkalemia is a serious risk, particularly in renal impairment, diabetes, or concurrent NSAID/potassium-sparing diuretic use—potassium monitoring is essential. Angioedema (0.1-0.2%) is a rare but life-threatening emergency, absolute contraindication for future ACE inhibitor use. Hypotension can occur in volume-depleted patients or those on concurrent vasodilators. Acute kidney injury risk exists in patients with bilateral renal artery stenosis or single kidney. Fetal teratogenicity is well-documented in pregnancy.
Contraindications
- xPregnancy (causes serious fetal harm)
- xHistory of angioedema with ACE inhibitors
- xSevere renal dysfunction
- xConcurrent use with certain other blood pressure medications
- xPotassium supplementation without medical supervision
Thymosin Beta-4
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- xActive systemic infections
- xSevere immunosuppression
- xHypersensitivity to thymosin or any component
- xPregnancy (insufficient safety data)
Decision Guide
Which is
right for you?
Choose Enalapril if...
- Managing hypertension to prevent serious complications
- Treating heart failure and improving survival rates
- Protecting organs from damage caused by high blood pressure
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation